New drug offers hope to free elderly patients from steroid side effects

NCT ID NCT07072988

Recruiting now Disease control Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

Summary

This study is testing if a newer drug called efgartigimod can help elderly patients with generalized myasthenia gravis safely reduce their steroid dose. Steroids are effective but cause serious side effects like diabetes and high blood pressure, especially in older adults. Researchers will observe 50 patients aged 65+ for one year to see if switching to efgartigimod allows them to lower their steroid use while controlling their muscle weakness.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS GENERALIZED are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

CHU de Nice
RECRUITING

Nice, Alpes-Maritimes, 06000, France

Contact Phone: •••-•••-••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MYASTHENIA GRAVIS GENERALIZED